RxDoctor Payments Data

John Winnie, MD

Family Medicine · Macon, GANPI 1053353938

Payments from drug & device makers

$985in general payments, 2019–2025

Across 36 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$264
  • Eisai Inc.$166
  • Novo Nordisk$126
  • Surgalign Spine Technologies, Inc.$87
  • AstraZeneca$83
  • Otsuka America Pharmaceutical, Inc.$67
  • plus $192 from 7 others

What the payments were for

  • Food & beverage$985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$985 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$27,545
Medicare patients
47
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$39,453
EliquisApixaban52$30,672
TrulicityDulaglutide14$13,763
LinzessLinaclotide24$12,949
MounjaroTirzepatide12$12,919
JanuviaSitagliptin Phosphate22$12,233
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen567$9,314
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,308
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen457$7,517
XareltoRivaroxaban14$7,322
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$5,491
Gabapentin432$5,281
Albuterol Sulfate HfaAlbuterol Sulfate207$5,124
BrilintaTicagrelor11$4,783
Diclofenac Sodium268$4,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$39,45339 claims
PfizerEliquis$53$30,67252 claims
AbbVieLinzess, Creon$264$16,84635 claims
AstraZenecaBrilinta, Symbicort$83$8,54827 claims
GSKTrelegy Ellipta$16$8,30813 claims
Eisai Inc.Dayvigo$166$3,57711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →